{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:49:43Z","timestamp":1786985383718,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bj.2025.100833","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:28:13Z","timestamp":1739636893000},"page":"100833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A long term bone and renal safety of TAF treatment on renal transplant recipients"],"prefix":"10.1016","volume":"48","author":[{"given":"Desmond Y.H.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie K.M.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Mao","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bj.2025.100833_bib1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJM197701272960404","article-title":"Long-term effect of hbs antigenemia on patient survival after renal transplantation","volume":"296","author":"Pirson","year":"1977","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bj.2025.100833_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00007890-198405000-00008","article-title":"The clinical and pathological course of hepatitis B liver disease in renal transplant recipients","volume":"37","author":"Parfrey","year":"1984","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bj.2025.100833_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-199607270-00025","article-title":"The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection","volume":"62","author":"Fornairon","year":"1996","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bj.2025.100833_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bj.2025.100833_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0016-5085(98)70380-4","article-title":"Treatment of fibrosing cholestatic hepatitis with lamivudine","volume":"115","author":"Chan","year":"1998","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bj.2025.100833_bib6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","article-title":"Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients","volume":"36","author":"Chan","year":"2002","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bj.2025.100833_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1600-6143.2004.00467.x","article-title":"Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients","volume":"4","author":"Chan","year":"2004","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.bj.2025.100833_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0b013e3181e5b811","article-title":"Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments","volume":"90","author":"Yap","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bj.2025.100833_bib9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.TP.0000116448.97841.6D","article-title":"Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials","volume":"77","author":"Fabrizi","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bj.2025.100833_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","article-title":"Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients","volume":"86","author":"Kamar","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bj.2025.100833_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3851\/IMP2097","article-title":"A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients","volume":"17","author":"Hu","year":"2012","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.bj.2025.100833_bib12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/ctr.12410","article-title":"Entecavir treatment in kidney transplant recipients infected with hepatitis B","volume":"28","author":"Yap","year":"2014","journal-title":"Clin Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.bj.2025.100833_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/ajt.12108","article-title":"Practice ASTIDCo. Viral hepatitis in solid organ transplantation","volume":"13","author":"Levitsky","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bj.2025.100833_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13143","article-title":"Long-term data on entecavir treatment for treatment-naive or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients","volume":"21","author":"Yap","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.bj.2025.100833_bib15","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/ndt\/gfr174","article-title":"Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B","volume":"26","author":"Lampertico","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.bj.2025.100833_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jfma.2011.05.010","article-title":"Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients","volume":"111","author":"Lai","year":"2012","journal-title":"J Formos Med Assoc"},{"issue":"8","key":"10.1016\/j.bj.2025.100833_bib17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/TP.0b013e3182100f59","article-title":"Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients","volume":"91","author":"Daude","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bj.2025.100833_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ndt\/gfh640","article-title":"Tenofovir-induced acute renal failure in an HIV patient with normal renal function","volume":"20","author":"Krummel","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.bj.2025.100833_bib19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cgh.2012.04.008","article-title":"Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B","volume":"10","author":"Gish","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bj.2025.100833_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bj.2025.100833_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bj.2025.100833_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2025.100833_bib23","doi-asserted-by":"crossref","unstructured":"Seto WK, Asahina Y, Brown TT, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 Years in patients with chronic HBV infection. Clin Gastroenterol Hepatol 2018; 20:S1542-3565(18)30633-5.","DOI":"10.1016\/j.cgh.2018.06.023"},{"issue":"10","key":"10.1016\/j.bj.2025.100833_bib24","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bj.2025.100833_bib25","article-title":"No resistance to tenofovir alafenamide detected through 96 Weeks of treatment in patients with chronic hepatitis B infection","volume":"62(10):e01064-18","author":"Cathcart","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.bj.2025.100833_bib26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"issue":"Pt 5","key":"10.1016\/j.bj.2025.100833_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1099\/jmm.0.05071-0","article-title":"Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes","volume":"52","author":"Ho","year":"2003","journal-title":"J Med Microbiol"},{"issue":"4","key":"10.1016\/j.bj.2025.100833_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B","volume":"16","author":"Seto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bj.2025.100833_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bj.2025.100833_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cgh.2022.01.035","article-title":"Renal outcomes with tenofovir alafenamide in liver transplant recipients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bj.2025.100833_bib31","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.938731","article-title":"Converting from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with hepatitis B following liver transplantation","volume":"28","author":"Cheng","year":"2023","journal-title":"Ann Transplant"},{"issue":"9","key":"10.1016\/j.bj.2025.100833_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.bj.2025.100833_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP2770","article-title":"Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity","volume":"19","author":"Bam","year":"2014","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.bj.2025.100833_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.bj.2025.100833_bib35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/QAD.0000000000002905","article-title":"Hypophosphatemia in people with HIV: no benefit when switching from tenofovir disoproxil fumarate to tenfovir alafenamide","volume":"35","author":"Sandmann","year":"2021","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.bj.2025.100833_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J Viral Hepat"},{"issue":"11\u201312","key":"10.1016\/j.bj.2025.100833_bib37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.17716","article-title":"Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: a nationwide claims study in South Korea","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417025000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417025000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:17:24Z","timestamp":1767889044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417025000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2319417025000071"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2025.100833","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A long term bone and renal safety of TAF treatment on renal transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2025.100833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"100833"}}